BET inhibitor

Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023

Retrieved on: 
Tuesday, March 14, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Molecule, Phosphatidylinositol, AACR, Lenalidomide, Lung cancer, APC Activator, Abstract, DLBCL, Clinical trial, Refractory, Anemia, Relapse, Potent, Tumor microenvironment, Phosphatase, BTK, BET inhibitor, Drug resistance, Bone marrow, MPN, Myeloproliferative neoplasm, ALK2, American Association for Cancer Research, Efficacy, Treatment, Fibroblast growth factor receptor, FGFR, Pharmaceutical industry, Vaccine, Patient, Macrophage, Incyte, Primary myelofibrosis, Pemigatinib

Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida.
  • ET)
    Five-Year Safety and Efficacy of Tafasitamab in Patients with Relapsed or Refractory DLBCL: Final Results from the Phase 2 L-MIND Study1(Abstract #CT022.
  • ET)
    For registered attendees, the virtual meeting platform and all on-demand sessions will be available through July 19, 2023.
  • More information regarding the AACR Annual Meeting 2023 can be found at https://www.aacr.org/meeting/aacr-annual-meeting-2023/ .

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Drugs In Development, 2021 Research Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Pharmaceutical, Health, Clinical trials, Bromodomain, BRD4, Branches of biology, BRD, Biology, BET inhibitor, BRD9

The "Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 43 molecules.
  • Bromodomain Containing Protein 4 - Drugs In Development, 2021, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects.

Bromodomain Testis Specific Protein Drug Development Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 14, 2021
Genetics, Pharmaceutical, Health, Branches of biology, Anatomy, Biology, BRDT, Bromodomain, Testicle, BET inhibitor, BRD9

The "Bromodomain Testis Specific Protein - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bromodomain Testis Specific Protein - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) pipeline Target constitutes close to 5 molecules.
  • The latest report Bromodomain Testis Specific Protein - Drugs In Development, 2021, outlays comprehensive information on the Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Bromodomain testis-specific protein is a protein encoded by the BRDT gene.

Resverlogix Announces Management Change

Retrieved on: 
Tuesday, July 6, 2021
BET inhibitor, Apabetalone, Television in the United States, Bromodomain, BET, Television, BET

CALGARY, Alberta, July 06, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that Ken Lebioda is stepping down as Senior Vice President, Business and Corporate Development, effective immediately.

Key Points: 
  • CALGARY, Alberta, July 06, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that Ken Lebioda is stepping down as Senior Vice President, Business and Corporate Development, effective immediately.
  • We would like to thank Ken for his important contributions over many years of service and wish him all the best, said Donald J. McCaffrey, President and CEO of the Company.
  • Resverlogix is developing apabetalone (RVX-208), a first-in-class small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor.
  • Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins.

Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada

Retrieved on: 
Thursday, June 3, 2021
Apabetalone, Quinazolinones, Bromodomain, BET inhibitor, BRD4

Apabetalone is an investigational, phase 3 clinical candidate with safety data in more than 4,200 man years of treatment.

Key Points: 
  • Apabetalone is an investigational, phase 3 clinical candidate with safety data in more than 4,200 man years of treatment.
  • As previously published, apabetalone has the potential to combat COVID-19 through a unique dual mechanism.
  • Apabetalone is also being studied for important benefits for patients with high-risk cardiovascular disease, chronic kidney disease and other indications while maintaining a well-described safety profile.
  • Resverlogix is developing apabetalone (RVX-208), a first-in-class small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor.

Resverlogix Announces US$6 Million Debenture Financing

Retrieved on: 
Wednesday, May 5, 2021
Finance, Money, Financial markets, Corporate finance, Debt, Fixed-income securities, Structured finance, Debenture, Warrant, Security, BET inhibitor, Tranche

The Company has agreed to grant Hepalink a security interest in all of its assets, including its patents and other intellectual property, as security for its obligations under the Debentures.

Key Points: 
  • The Company has agreed to grant Hepalink a security interest in all of its assets, including its patents and other intellectual property, as security for its obligations under the Debentures.
  • In addition, Hepalink will receive an aggregate of 300,000 common share purchase warrants exercisable for a period of four years from the first closing date of the Debenture Financing at a price of CAD$0.93 per share (the \xe2\x80\x9cWarrants\xe2\x80\x9d).\nThe completion of the Debenture Financing is subject to satisfaction of customary conditions for a transaction of this nature, including the approval of the Toronto Stock Exchange.
  • The Company plans to complete the Debenture Financing by issuing the Debentures and Warrants to Hepalink in two equal tranches, with the first tranche scheduled to be completed upon satisfaction of all closing conditions in the next three days and the second tranche to be completed by May 31, 2021.\nThe Company has a total of 238,766,021 common shares issued and outstanding.
  • Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins.

Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease

Retrieved on: 
Tuesday, April 27, 2021
Clinical medicine, Medicine, Anatomy, Cardiovascular diseases, Kidney diseases, Apabetalone, Quinazolinones, Chronic kidney disease, BET inhibitor, Diabetes, Cardiovascular disease, Hemodialysis, Clinical medicine, Medicine, Anatomy, Cardiovascular diseases, Kidney diseases, Apabetalone, Quinazolinones, Chronic kidney disease, BET inhibitor, Diabetes, Cardiovascular disease, Hemodialysis

\xe2\x80\x9cIn a prespecified analysis of the BETonMACE study, patients with CKD experienced significantly fewer major adverse cardiovascular events when treated with apabetalone compared to placebo.

Key Points: 
  • \xe2\x80\x9cIn a prespecified analysis of the BETonMACE study, patients with CKD experienced significantly fewer major adverse cardiovascular events when treated with apabetalone compared to placebo.
  • This finding demonstrates that apabetalone may offer a safe and effective treatment option for this high-risk group of patients.
  • Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins.
  • This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.\n'

Constellation Pharmaceuticals to Host Conference Call to Discuss First Quarter 2021 Results

Retrieved on: 
Tuesday, April 27, 2021
Branches of biology, EZH2, CPI-0610, BET inhibitor, Cancer, Biology, Epigenetics, Branches of biology, EZH2, CPI-0610, BET inhibitor, Cancer, Biology, Epigenetics, Branches of biology, EZH2, CPI-0610, BET inhibitor, Cancer, Biology, Epigenetics

b'CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 10, 2021, to discuss its first quarter 2021 results and provide a business update.

Key Points: 
  • b'CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 10, 2021, to discuss its first quarter 2021 results and provide a business update.
  • The event will be webcast live and can be accessed on the Investor Relations section of Constellation\xe2\x80\x99s website at http://ir.constellationpharma.com/events-and-presentations/events.
  • The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance.
  • Constellation is driving development of the BET inhibitor pelabresib (CPI-0610) for the treatment of myelofibrosis as well as its EZH2 inhibitor CPI-0209 for the treatment of other cancers.

Apabetalone’s Positive Impact on COVID-19 in Human Lung Cells Published in Biomedicines

Retrieved on: 
Tuesday, April 20, 2021
Medical specialties, Health, Angiotensin-converting enzyme 2, BET inhibitor, Apabetalone, Cytokine storm, COVID-19, Bromodomain

b'CALGARY, Alberta, April 20, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today the publishing of an article titled: \xe2\x80\x9cBromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro\xe2\x80\x9d, in Biomedicines, a high-impact scientific journal.

Key Points: 
  • b'CALGARY, Alberta, April 20, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today the publishing of an article titled: \xe2\x80\x9cBromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro\xe2\x80\x9d, in Biomedicines, a high-impact scientific journal.
  • Resverlogix is advancing an open-label study to assess the safety and efficacy of apabetalone in the treatment of COVID-19, following a recent authorization from Health Canada.\nAs previously announced , an article published on March 23, 2020 revealed the interaction between SARS-CoV-2 (COVID-19) protein E with BET proteins.
  • First, apabetalone treatment prevents SARS-CoV-2 from infecting human cells , and second it reduces the inflammation and cytokine storm response which can result in organ damage and long-term negative impacts.
  • Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins.

Resverlogix Announces Update Webcast and Conference Call

Retrieved on: 
Monday, January 18, 2021
BET inhibitor, Bromodomain, Apabetalone, BET, Area code 246, Rotary dial, Toll-free telephone number, Communication

If dialing in by phone, dial 1-800-319-4610 (within Canada / USA) or +1-403-351-0324 (International Toll).

Key Points: 
  • If dialing in by phone, dial 1-800-319-4610 (within Canada / USA) or +1-403-351-0324 (International Toll).
  • Callers should dial-in at least 10 min prior to the scheduled start time.
  • Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor.
  • Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins.